Portal CEO on Lilly Deal for Cancer Biotech CrossBridge

This is a live story built from multiple sources. It may evolve quickly.

Coverage meter • 1 min window

Back to home Open top source

B bloomberg.com

What’s included

Top recent items from this story.

1 items • 1 unique links

Bloomberg Markets 2 days ago • bloomberg.com

Portal CEO on Lilly Deal for Cancer Biotech CrossBridge

Portal Innovations CEO John Flavin provides a look into the 2026 biotech M&A pipeline and breaks down Eli Lilly’s purported acquisition of CrossBridge Bio for up to $300 million, bolstering its oncology segment. He talks…

Open